Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Citius Oncology Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Citius Oncology Inc. market cap is $147.34M.
What is the 52-week high for Citius Oncology Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Citius Oncology Inc. 52 week high is $6.19 as of September 07, 2025.
What is the 52-week low for Citius Oncology Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Citius Oncology Inc. 52 week low is $0.5506 as of September 07, 2025.
What is Citius Oncology Inc. stock price today?
Citius Oncology Inc. stock price today is $1.88.
What was Citius Oncology Inc. stock price yesterday?
Citius Oncology Inc. stock price yesterday was $1.87.
What is the PE ratio of Citius Oncology Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Citius Oncology Inc.’s P/E ratio is -9.87.
What is the Price-to-Book ratio of Citius Oncology Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Citius Oncology Inc. P/B ratio is 4.1520.
What is the 50-day moving average of Citius Oncology Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Citius Oncology Inc. 50-day moving average is $2.39.
